Modality
mAb
MOA
DLL3 ADC
Target
PLK4
Pathway
Sphingolipid
MS
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
Jan 2020
→ Apr 2027
Phase 1Current
NCT08662967
1,177 pts·MS
2020-01→TBD·Active
NCT05010370
1,079 pts·MS
2022-12→2027-04·Terminated
2,256 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-04-141.0y awayPh2 Data· MS
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1/2
Active
P1/2
Termina…
Catalysts
Ph2 Data
2027-04-14 · 1.0y away
MS
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08662967 | Phase 1/2 | MS | Active | 1177 | NT-proBNP |
| NCT05010370 | Phase 1/2 | MS | Terminated | 1079 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| ROI-3353 | Roivant Sciences | Phase 1/2 | PLK4 | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 |